by Maria Dalby reporting on the presentation by Rajeev Desai, National Health Service Blood and Transplant, Bristol. The risk of cancer transmission via transplanted organs is very low… read more.
New research, presented at the 54th Annual Meeting of the American Society of Haematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that… read more.
by Sung Choi, M.D., University of Michigan Comprehensive Cancer Center (pictured) First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic… read more.
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome,
Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Women treated for childhood cancer with chest radiation therapy have a high risk of developing breast cancer at a young age, comparable to that… read more.
by Marybeth Burke – Wisconsin grown ginseng significantly reduced cancer related fatigue in patients receiving cancer treatment after 8 weeks of ginseng treatment,
by Bruce Sylvester – Emerging use of FDA Approved Drugs – Maraviroc, an antiretroviral drugin the treatment of HIV, significantly reduces the incidence of graft-versus-host disease (GvHD) among… read more.
by Bruce Sylvester – Investigators reported at ASCO that relapsed follicular lymphoma patinets treated with combination lenalidomide (Revlimid) and rituximab (Rituxan) achieved a higher percentage of overall response… read more.
by Bruce Sylvester – In a phase I study presented at ASCO, researchers reported that crizotinib (Xalkori) stalled tumor growth and, in some cases, eradicated all signs of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
